MLST8 promotes mTOR-mediated tumor progression

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Kakumoto, Kyoko ^a,c   Ikeda, Jun Ichiro ^b   Okada, Masato ^a   Morii, Eiichi ^b   Oneyama, Chitose ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c RIKEN   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN KINASE B; PROTEIN MLST8; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; EIF4EBP1 PROTEIN, HUMAN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MLST8 PROTEIN, HUMAN; MULTIPROTEIN COMPLEX; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION; COLON CANCER; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; GENE SILENCING; HCT116 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LNCAP CELL LINE; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR INVASION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA; CELL LINE; COLON TUMOR; DISEASE COURSE; GENETICS; HCT 116 CELL LINE; HT-29 CELL LINE; PATHOLOGY; PHOSPHORYLATION; PROSTATE TUMOR; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CARCINOMA; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; DISEASE PROGRESSION; EPITHELIAL CELLS; HCT116 CELLS; HT29 CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MULTIPROTEIN COMPLEXES; PHOSPHOPROTEINS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES; UP-REGULATION;

EID: 84929359506     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0119015     Document Type: Article

References (39)

1. Barbet NC, Schneider U, Helliwell SB, Stansfield I, Tuite MF, Hall MN. TOR controls translation initiation and early G1 progression in yeast. Mol Biol Cell. 1996; 7:25-42. PMID: 8741837
2. Di Como CJ, Arndt KT. Nutrients, via the Tor proteins, stimulate the association of Tap42 with type 2A phosphatases. Genes Dev. 1996; 10:1904-1916. PMID: 8756348
3. Schmidt A, Beck T, Koller A, Kunz J, Hall MN. The TOR nutrient signalling pathway phosphorylates NPR1 and inhibits turnover of the tryptophan permease. Embo j. 1998; 17:6924-6931. PMID: 9843498
4. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000; 103:253-262. PMID: 11057898
5. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene. 2006; 25:6416-6422. PMID: 17041626
6. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004; 18:1926-1945. PMID: 15314020
7. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005; 307:1098-1101. PMID: 15718470
8. Facchinetti V, Ouyang W, Wei H, Soto N, Lazorchak A, Gould C, et al. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J. 2008; 27:1932-1943. doi: 10.1038/emboj.2008.120 PMID: 18566586
9. Oneyama C, Ikeda J, Okuzaki D, Suzuki K, Kanou T, Shintani Y, et al. MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. Oncogene. 2011; 30:3489-3501. doi: 10.1038/onc.2011.63 PMID: 21383697
10. Oneyama C, Kito Y, Asai R, Ikeda J, Yoshida T, Okuzaki D, et al. MiR-424/503-mediated Rictor upregulation promotes tumor progression. PLoS One. 2013; 8:e80300. doi: 10.1371/journal.pone.0080300 PMID: 24244675
11. Evren S, Dermen A, Lockwood G, Fleshner N, Sweet J. mTOR-RAPTOR and 14-3-3sigma immunohistochemical expression in high grade prostatic intraepithelial neoplasia and prostatic adenocarcinomas: a tissue microarray study. J Clin Pathol. 2011; 64:683-688. doi: 10.1136/jclinpath-2011-200083 PMID: 21653658
12. Xu J, Li X, Yang H, Chang R, Kong C, Yang L. SIN1 promotes invasion and metastasis of hepatocellular carcinoma by facilitating epithelial-mesenchymal transition. Cancer. 2013; 119:2247-2257. doi: 10.1002/cncr.28023 PMID: 23564492
13. Madhunapantula SV, Sharma A, Robertson GP. PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res. 2007; 67:3626-3636. PMID: 17440074
14. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell. 2009; 137:873-886. doi: 10.1016/j.cell.2009.03.046 PMID: 19446321
15. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, et al. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell. 2009; 15:148-159. doi: 10.1016/j.ccr.2008.12.017 PMID: 19185849
16. He J, Wang MY, Qiu LX, Zhu ML, Shi TY, Zhou XY, et al. Genetic variations of mTORC1 genes and risk of gastric cancer in an Eastern Chinese population. Mol Carcinog. 2013; 52 Suppl 1:E70-79. doi: 10.1002/mc.22013 PMID: 23423739
17. Slattery ML, Herrick JS, Lundgreen A, Fitzpatrick FA, Curtin K, Wolff RK. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1. Carcinogenesis. 2010; 31:1604-1611. doi: 10.1093/carcin/bgq142 PMID: 20622004
18. Chen M, Cassidy A, Gu J, Delclos GL, Zhen F, Yang H, et al. Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis. 2009; 30:2047-2052. doi: 10.1093/carcin/bgp258 PMID: 19875696
19. Lin J, Wang J, Greisinger AJ, Grossman HB, Forman MR, Dinney CP, et al. Energy balance, the PI3K-AKT-mTOR pathway genes, and the risk of bladder cancer. Cancer Prev Res (Phila). 2010; 3:505-517. doi: 10.1158/1940-6207.CAPR-09-0263 PMID: 20354165
20. Liu Q, Thoreen C, Wang J, Sabatini D, Gray NS. mTOR Mediated Anti-Cancer Drug Discovery. Drug Discov Today Ther Strateg. 2009; 6:47-55. PMID: 20622997
21. Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal. 2009; 2:pe24. doi: 10.1126/scisignal.267pe24 PMID: 19383975
22. Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ, Pavletich NP. mTOR kinase structure, mechanism and regulation. Nature. 2013; 497:217-223. doi: 10.1038/nature12122 PMID: 23636326
23. Kim DH, Sarbassov DD, Ali SM, Latek RR, Guntur KV, Erdjument-Bromage H, et al. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell. 2003; 11:895-904. PMID: 12718876
24. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, et al. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt- FOXO and PKCalpha, but not S6K1. Dev Cell. 2006; 11:859-871. PMID: 17141160
25. Nakashima A, Kawanishi I, Eguchi S, Yu EH, Eguchi S, Oshiro N, et al. Association of CAD, a multifunctional protein involved in pyrimidine synthesis, with mLST8, a component of the mTOR complexes. J Biomed Sci. 2013; 20:24. doi: 10.1186/1423-0127-20-24 PMID: 23594158
26. Robitaille AM, Christen S, Shimobayashi M, Cornu M, Fava LL, Moes S, et al. Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science. 2013; 339:1320-1323. doi: 10.1126/science.1228771 PMID: 23429704
27. Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, et al. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2010; 70:5184-5193. doi: 10.1158/0008-5472.CAN-10-0145 PMID: 20501828
28. Doghman M, El Wakil A, Cardinaud B, Thomas E, Wang J, Zhao W, et al. Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Res. 2010; 70:4666-4675. doi: 10.1158/0008-5472.CAN-09-3970 PMID: 20484036
29. Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, Reid JG, et al. A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol. 2010; 24:447-463. doi: 10.1210/me.2009-0295 PMID: 20081105
30. Tsuruta T, Kozaki K, Uesugi A, Furuta M, Hirasawa A, Imoto I, et al. miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res. 2011; 71:6450-6462. doi: 10.1158/0008-5472.CAN-11-0364 PMID: 21868754
31. Uesugi A, Kozaki K, Tsuruta T, Furuta M, Morita K, Imoto I, et al. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res. 2011; 71:5765-5778. doi: 10.1158/0008-5472.CAN-11-0368 PMID: 21795477
32. Yang Q, Inoki K, Ikenoue T, Guan KL. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev. 2006; 20:2820-2832. PMID: 17043309
33. Liu P, Gan W, Inuzuka H, Lazorchak AS, Gao D, Arojo O, et al. Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis. Nat Cell Biol. 2013; 15:1340-1350. doi: 10.1038/ncb2860 PMID: 24161930
34. Nawroth R, Stellwagen F, Schulz WA, Stoehr R, Hartmann A, Krause BJ, et al. S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer. PLoS One. 2011; 6:e27509. doi: 10.1371/journal.pone.0027509 PMID: 22110663
35. Armengol G, Rojo F, Castellvi J, Iglesias C, Cuatrecasas M, Pons B, et al. 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res. 2007; 67:7551-7555. PMID: 17699757
36. Nojima H, Tokunaga C, Eguchi S, Oshiro N, Hidayat S, Yoshino K, et al. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem. 2003; 278:15461-15464. PMID: 12604610
37. Frey JW, Jacobs BL, Goodman CA, Hornberger TA. A role for Raptor phosphorylation in the mechanical activation of mTOR signaling. Cell Signal. 2014; 26:313-322. doi: 10.1016/j.cellsig.2013.11.009 PMID: 24239769
38. Oneyama C, Morii E, Okuzaki D, Takahashi Y, Ikeda J, Wakabayashi N, et al. MicroRNA-mediated upregulation of integrin-linked kinase promotes Src-induced tumor progression. Oncogene. 2012; 31:1623-1635. doi: 10.1038/onc.2011.367 PMID: 21860426
39. Akagi T, Sasai K, Hanafusa H. Refractory nature of normal human diploid fibroblasts with respect to oncogene-mediated transformation. Proc Natl Acad Sci USA. 2003; 100:13567-13572. PMID: 14597713